Autores cubanos: nasalferón, nimotuzumab

– Vázquez-Blomquist D, Bequet-Romero M, Mendoza-Marí Y, Lemos G, Valdés I, Canaán-Haden C, et al. Nasalferon, a new nasal formulation of IFNa2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood. Clinical Immunology Communications, 2022;2:39-45.
– González S, Amador Y, Boris LG, Mojena L, Soler LL, Pish G, et al. Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin. J Oncol. 2022 Sep 1;2022:4128946.